Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma by Christiane Querfeld, Joycelynne Palmer, Zhen Han, Xiwei Wu, Yate-Ching Yuan, Min-Hsuan Chen, Chingyu Su, Ni-Chun Tsai, D. Lynne Smith, Samantha N. Hammond, Liliana Crisan, Joo Y. Song, Raju Pillai, Steven T. Rosen, Jasmine Zain

Get full text